Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a Specialized Prostate-specific Membrane Antigen (PSMA) Labeled With Lutetium177, in Patients With Recurrent and/or Metastatic Adenoid Cystic Carcinoma Originating From the Salivary Glands - an Open, Non-commercial Clinical Trial

Next Previous
X
Search
Trial Profile

The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a Specialized Prostate-specific Membrane Antigen (PSMA) Labeled With Lutetium177, in Patients With Recurrent and/or Metastatic Adenoid Cystic Carcinoma Originating From the Salivary Glands - an Open, Non-commercial Clinical Trial

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
  • Indications Adenoid cystic carcinoma; Salivary gland cancer
  • Focus Therapeutic Use
  • Acronyms LuRM_ACC/2023

    • Most Recent Events

    • 10 Feb 2025 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 12 Jan 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top